-
Description
This medicine contains; empagliflozin and metformin as its ingredients. Empagliflozin, an orally-active inhibitor of the sodium-glucose co-transporter 2 (SGLT2). Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus as: Monotherapy when diet and exercise alone do not provide adequate glycemic control in patients for whom use of metformin is considered inappropriate due to intolerance. In combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycemic control. Metformin (N, N-dimethylbiguanide) belongs to the biguanide class of antidiabetic drugs (containing two linked guanidine rings). This drug has a major clinical advantage that it does not induce hypoglycemia or weight gain with remarkable cardiovascular safety. Metformin is also used for the treatment of polycystic ovary disease, diabetic nephropathy, and gestational diabetes. Metformin acts via both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent mechanisms; by inhibiting mitochondrial respiration and inhibiting mitochondrial glycerophosphate dehydrogenase, and a mechanism involving the lysosome. Metformin acts directly or indirectly on the liver in order to reduce glucose production, and acts on the gut to increase glucose utilization. At the molecular level, metformin acts to inhibit the mitochondrial respiratory chain in the liver, that results in activation of AMPK, enhances insulin sensitivity (via effects on fat metabolism) and lowers cAMP, and reduces the expression of gluconeogenic enzymes. Metformin shows AMPK-independent effects on the liver that results in inhibition of fructose-1,6-bisphosphatase by AMP.
-
Ingredients
-
Dosage Form
-
Uses
Co-Amoxiclav is utilized for the following therapeutic indications:
- Treatment of respiratory tract infections, including pneumonia and sinusitis
- Management of urinary tract infections
- Treatment of skin and soft tissue infections
- Support for intra-abdominal infections
- Management of gynecological infections
-
Dosage
Dose must be taken according to the doctor’s advice only; doses given below are suggested as supportive literature for better understanding in some areas of requirements. Adult dose: 1 or 2 tablets per day, doctor would recommend the dose according to patient’s condition The maximum daily dose of empagliflozin is 25mg. And maximum daily dose of metformin is 2000mg per day.
-
In case of Overdose
Overdose may lead to hypoglycemia, consult your doctor immediately in case of overdose. Multiple daily doses of up to 100mg empagliflozin (equivalent to 4 times the highest recommended daily dose) in patients with type 2 diabetes did not show any toxicity.
-
Missed Dose
In case you missed any dose, take the next dose as soon as you remember, but don't double your next dose to compensate for the missed one.
-
How To Use
Take it orally as advised by the doctor.
-
When Not to Use
Empagliflozin is contraindicated in: Patients with known hypersensitivity to empagliflozin or to any excipient of the product, Severe renal impairment, end-stage renal disease or dialysis. Metformin should not be used in case of hypersensitivity to the drug, metabolic acidosis, chronic heart failure, myocardial infarction, diabetic ketoacidosis, severe renal disease, abnormal creatinine clearance resulting from shock, septicemia and lactation.
-
Side Effects
Hypoglycemia (When Used With Sulfonylurea Or Insulin) Vaginal Moniliasis Vulvovaginitis Balanitis And Other Genital Infection Urinary Tract Infection Pruritus (Generalized) And Increased Urination Uncommon; Volume Depletion Dysuria And Blood Creatinine Increased / Glomerular Filtration Rate Decreased Rare; Diabetic Ketoacidosis. Metformin May Cause Vomiting, Stomach Ache, Loss Of Appetite, Constipation And Weight Loss.
-
Precautions & Warnings
Empagliflozin causes intravascular volume contraction. Symptomatic hypotension may occur after initiating empagliflozin particularly in patients with renal impairment. Empagliozin increases serum creatinine and decreases eGFR. The risk of impaired renal function with empagliflozin is increased in elderly patients and patients with moderate renal impairment. Assess renal function prior to initiation of this drug. If metformin-associated lactic acidosis occurs then general supportive measures should be taken in a hospital setting, along with immediate discontinuation of this medicine.
-
Food Interactions
Diet management is necessary with the use of hypoglycemic drugs. Keep a strict check on your carbohydrate intake specially. Taking grapefruit along with this medicine could increase the accumulation of metformin in the liver and in result increases the risk of lactic acidosis. Taking metformin with a meal can reduce the chances of developing an upset stomach or gastric discomfort.
-
Storage/Disposal
If you are diabetic, go for the following tests: Glucose Tolerance Test, Blood sugar test.